Sunday - June 14, 2026
Fixed-Duration Triplet Therapy Demonstrates Efficacy for Patients with Relapsed/Refractory CLL
June 14, 2026
BOSTON, Massachusetts, June 14 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:

* * *

Fixed-Duration Triplet Therapy Demonstrates Efficacy for Patients with Relapsed/Refractory CLL

*

A Dana-Farber Cancer Institute investigator presented positive interim data from the BRUIN CLL-322 trial, the first randomized phase 3 data to be reported about a Bruton tyrosine kinase (BTK) inhibitor as part of a fixe . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products